Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | -$0 |
| G&A Expenses | $1 | $1 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 | $1 |
| Operating Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $1 | $0 | -$0 |
| Pre-Tax Income | -$2 | $0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | $0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.068 | 0.005 | -2.55 | -0.12 |
| % Growth | -1,477.6% | 100.2% | -2,025% | – |
| EPS Diluted | -0.068 | 0.005 | -2.55 | -0.12 |
| Weighted Avg Shares Out | 27 | 23 | 27 | 7 |
| Weighted Avg Shares Out Dil | 27 | 23 | 27 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | $0 | -$0 | -$1 |
| % Margin | – | – | – | – |